Group items tagged

A three-year contract has been signed between NHS Education for Scotland (NES) and Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business, to continue the supply of trusted medicines information though MedicinesComplete, to healthcare professionals in Scotland. The renewed investment from NES demonstrates unequivocal confidence in the publisher and highlights Pharmaceutical Press' ongoing commitment to provide practical and evidence-based guidance, supporting those who prescribe, dispense, and administer medicines. Essential resources include Martindale: The Complete Drug Reference, Palliative Care formulary, Stockley's Drug Interactions and Critical Illness. Relied on by healthcare professionals globally for use in everyday practice, clear and concise guidance through MedicinesComplete supports confident decision-making at the point of care.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

The Royal Pharmaceutical Society (RPS) has awarded Professor Abdul Basit with the RPS Harrison Memorial Medal for an outstanding contribution to advancing pharmaceutical science. Professor Basit graduated with a First Class Honours degree in Pharmacy from the University of Bath, and received his PhD from The School of Pharmacy, University of London. Currently in position as Professor of Pharmaceutics at the UCL School of Pharmacy, he is internationally recognised for leading in the field of drug delivery, microbiome medicines, three-dimensional printing of pharmaceuticals and digital health. He has also founded three start-up companies. Professor Basit has an impressive track record of publications, and a lifetime grant and investment income of over £100million pounds. His research has led to a series of transformative drug delivery systems, translated into the design of new technologies and improved therapies, many of which have been commercialised and launched worldwide including a new treatment for inflammatory bowel disease. To date, more than a million patients have benefited from inventions created and developed in the Basit Research Group.

Well Pharmacy has announced the acquisition of Lexon UK Holdings and Asurex Limited, a family-owned pharmaceutical wholesaler with five depots in Redditch, Leeds, Durham, East Kilbride and Dublin and a network of community pharmacies across the Midlands, Northwest, and Northeast of England. Lexon, is a family-owned business which has been in operation for over 25 years, running primarily as a pharmaceutical wholesaler for 3,000 retail pharmacy customers across the UK and Ireland. The business also operates 42 community pharmacies - currently trading as Knights Pharmacy - and is also a specialist developer and manufacturer of generic pharmaceuticals and is a data and solutions provider to pharmacy. The acquisition will be notified to the Competition and Markets Authority (CMA). Both parties have proactively engaged with the CMA in pre-notification discussions and look forward to continuing to do so productively during the CMA review period. Haider Choudrey, CFO of Bestway Group which own Well Pharmacy, said: "Through this acquisition we seek to augment our growth momentum and bring in even greater benefits to both community pharmacies and patients. Well Pharmacy had been searching for a target to expand its footprint and complement its growth trajectory and we are confident that Lexon fits this criterion."

In a first, NHS England and NHS Improvement (NHSE&I) has appointed a pharmacy technician to the chief pharmaceutical officer's team. Liz Fidler, president at the Association of Pharmacy Technicians UK (APTUK), will join the team in March 2022 in the newly created post of senior professional advisor: pharmacy technician practice NHSE&I. The appointment signaled "a new era for the profession, leading the step-change needed to build on and fully realise the benefits of the pharmacy technician clinical role for patients across the NHS system," said Dr Keith Ridge, chief pharmaceutical officer. In the new role, Fidler will provide leadership and professional advice in relation to the pharmacy technician profession in England.

David Webb has been appointed as the new chief pharmaceutical officer (CPO) for England. He will take over from Dr Keith Ridge who steps down next month after serving the role for sixteen year. Webb is currently chief pharmacist and clinical director for pharmacy and medicines optimisation at Guy's and Thomas's NHS Foundation Trust, London. Sharing the news of his appointment on Twitter on Friday afternoon (January 7), he said he was "really delighted and honoured" to be named the CPO for NHS England and that he was as the appointed Chief Pharmaceutical officer for "looking forward to working with pharmacy leaders, colleagues & teams across all sectors from February." He also extended his gratitude to the outgoing CPO for his "outstanding contribution" who, in turn, congratulated Webb and said it was "an honour to be handing over to him". In the same message, Dr Ridge thanked "all the great people I've worked with over the last 16 years for your support, friendship, good humour, great ideas & challenge. I wish you all well for the future."

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for selling adulterated or fake products, a government source said on Thursday. India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22. But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by India-based pharmaceutical companies. Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken. "There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event. Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had direct knowledge of the matter, told Reuters news agency.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.

European asset management group Aurelius has completed the acquisition of McKesson UK, marking the company's fifth completed transaction in a year. McKesson UK is the parent company of a number of healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. It comprises four divisions and holds a substantial market share across each vertical: retail, digital, homecare and wholesale. McKesson UK's success has been underpinned by its strong LloydsPharmacy brand, its customer base and its leading commercial footprint across wholesale pharmaceuticals. Over recent years, the company has benefited from the introduction of additional services delivered across its more than 1,300 pharmacies, a growing digital offering and the ability to support the increasing trend of primary care being delivered to patients in their home.

The Royal Pharmaceutical Society (RPS) has appointed Professor Parastou Donyai as chief scientist. She will take up the role in June. Parastou is a pharmacist with a PhD in pharmacy. She also has a postgraduate diploma in Psychological Research Methods as well as a degree in Psychology. She is currently a professor of Social & Cognitive Pharmacy at the University of Reading and her research examines the psychology of medication use, discontinuation and decision-making processes. Prior to this, Parastou also spent more than five years as a senior lecturer in Pharmacy Practice at Kingston University and St. George's University of London. Her longstanding research interest includes continuing professional development in pharmacy. Commenting on her appointment, Parastou said: "It is a real privilege for me to be the Royal Pharmaceutical Society's next chief scientist. "As a pharmacist, scientist and academic, I look forward to working with the Royal Pharmaceutical Society's members and key stakeholders to uphold the value of science across the breadth of our profession."

The Royal Pharmaceutical Society (RPS) has re-joined the International Pharmaceutical Federation (FIP) after reflecting its commitment to international collaboration and the advancement of the pharmacy profession. RPS President Professor Claire Anderson said: "Members told us they wanted to see us re-join FIP to further our commitment to international partnerships which support education and advocacy to develop and progress the pharmacy profession.". "We fully recognise the importance of international collaboration and the sharing of knowledge and best practice with our peers across the world. "FIP are refocusing their membership offer and we're delighted to work with them on opportunities for professional development and increased visibility and recognition for the pharmacy profession." Paul Bennett, RPS CEO said: "Now that we have re-joined, our teams across RPS look forward to reinvigorating the close collaboration we have previously enjoyed with our colleagues both within FIP itself, and across the breadth of FIP Member organisations to further our vision and mission".

AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer. "I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for our customers and building and strengthening our supplier partnerships." Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role in the organisation was on Sales and Marketing Director. He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale business focussed on only the AAH customer and our core business and this is just one part of that.

The UK Commission on Pharmacy Professional Leadership set up by the Chief Pharmaceutical Officers of England, Northern Ireland, Scotland and Wales has published its recommendations for the 'future of pharmacy professional leadership in the UK' on Monday (6 February). The Commission is co-chaired by Nigel Clarke, Former Chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, Professor of Medical Education at University College London Medical School. The Commission proposes that closer collaboration between professional leadership bodies and specialist professional groups as part of a Pharmacy Leadership Council will enable and support pharmacists and pharmacy technicians to meet the opportunities and challenges ahead. The Council will be set up in 2023 to lead the implementation of the report's vision and recommendations over five years. Commission Co-Chairs, Professor Dame Jane Dacre and Nigel Clarke: "The Commission has set out a collaborative approach to transform pharmacy professional leadership and deliver sustained benefits for patients and the public and pharmacy professionals in the UK.

Pharmaceutical giant Bristol Myers Squibb has become the first pharmaceutical company in the UK to be accredited as a 'menopause friendly workplace'. The accreditation, awarded by an independent panel of judges, recognises employers who put diversity, inclusion and wellbeing at the centre stage of their business. Bristol Myers Squibb (BMS) said it rung in the changes in recognition of the fact that nearly eight of 10 menopausal women are in work and that this is the fastest growing demographic in the workforce. Panel members described BMS UK&I's application as "outstanding" and acknowledged "the huge strides they have made to help normalise the menopause" by fostering an inclusive culture.

The Competition and Markets Authority(CMA) has disqualified a former director of the pharmaceutical wholesaler Lexon for allegedly breaking competition law. Pritesh Sonpal - who has been accused of illegally sharing commercially sensitive information with competitors - will not be allowed to take up any director role or be involved in the management of any company based in England, Scotland or Wales for four years. The CMA in March 2020 found that Lexon - along with the pharmaceutical companies King Pharmaceuticals and Alissa Healthcare Research - illegally shared commercially sensitive information about the antidepressant nortriptyline, used by thousands of NHS patients, to inflate the price. Lexon was fined £1.2 million for breaking competition law. The government watchdog said between 2015 and 2017, when the cost of the drug was falling, the three companies exchanged information about prices, the volumes they were supplying and Alissa's plans to enter the market, in order to reduce competition.

The Local Pharmaceutical Committees (LPCs) has rebranded to be known as Community Pharmacy to present a strengthened and unified identity to the local NHS, local government and other stakeholders, as the local voice of community pharmacy. "There are now 58 LPCs in England. The number of LPCs has reduced from 69, with further consolidation expected by April 2024 to a network of 48 local organisations," said Community Pharmacy England. "The changes mean there will be better alignment between LPCs and the 42 NHS Integrated Care Systems in England, who have taken on the responsibility for commissioning pharmaceutical services delegated by NHS England." "This marks a significant milestone, as similar to Community Pharmacy England, LPCs have been undergoing changes to respond to the Review Steering Group (RSG) recommendations on pharmacy representation. The sector voted in favour of the RSG proposals in the summer of 2022, and since then progress has been made on many of the changes at both local and national level as part of the Transforming Pharmacy Representation (TAPR) Programme."

AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company. In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations, and trading. Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."

In many cases, a pharmacy's most valuable asset is its NHS contract. This is what buyers are paying for - the right to provide pharmaceutical services commissioned by the NHS and be reimbursed for the medicines dispensed. However, a pharmacy consists of more than just an NHS contract and when buyers look for a pharmacy to buy, they will also examine these other areas - the pharmacy's customer base, its staff, the property it operates from - to name a few - because these are all also crucial to a successful pharmacy. In this day and age, another important consideration is the pharmacy's intellectual property (IP) i.e. the pharmacy's rights to certain types of information, ideas, and forms of expression. At the most basic level, this includes the trade mark in the name of the pharmacy, because all pharmacies will have a name by which they distinguish themselves from other pharmacies. The more well-known the name, the more valuable this form of IP is - mention 'Boots', for example, and most will have an instant association with the largest pharmaceutical retailer in the UK.